Advertisement

European Journal of Epidemiology

, Volume 30, Issue 3, pp 219–230 | Cite as

Serum osteoprotegerin and future risk of cancer and cancer-related mortality in the general population: the Tromsø study

  • Anders Vik
  • Ellen E. Brodin
  • Ellisiv B. Mathiesen
  • Jan Brox
  • Lone Jørgensen
  • Inger Njølstad
  • Sigrid K. Brækkan
  • John-Bjarne Hansen
CANCER

Abstract

The purpose was to investigate the association between serum osteoprotegerin (OPG) and risk of incident cancer and cancer mortality in a general population. OPG was measured in serum collected from 6,279 subjects without prior cancer recruited from a general population. Incident cancer and cancer-related mortality were registered from inclusion in 1994–95 until end of follow-up December 31, 2008. Cox regression models were used to estimate crude and adjusted (for age, sex and other confounders) hazard ratios and 95 % confidence intervals (HR 95 % CI). There were 948 incident cancers and 387 deaths in the cohort during 71,902 person-years of follow up (median 13.5 years). Subjects with serum OPG in the upper tertile had 79 % higher risk of incident gastrointestinal cancer than those in the lowest tertile (HR 1.79, 95 % CI 1.19–2.67). In women <60 years, serum OPG (per SD 0.81 ng/ml) was associated with reduced risk of incident cancer (all cancers merged; 0.73; 0.57–0.94) and breast cancer (0.51; 0.31–0.83) after adjustment. Subjects in the upper tertile of OPG had higher risk of cancer-related mortality (1.63; 1.16–2.28), particularly mortality from cancer in the gastrointestinal system (2.28; 1.21–4.28) compared to those in the lowest OPG tertile. No significant association was detected between OPG and risk of death from cancer in the respiratory system or death from prostatic cancer. Our findings from a large population based cohort study suggest that serum OPG was associated with increased risk of incident gastrointestinal cancer, inversely associated with breast cancer, and predicts cancer-related mortality.

Keywords

Osteprotegerin Incident cancer Mortality 

Notes

Conflict of interest

The authors disclose no potential conflicts of interest.

References

  1. 1.
    Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. PNAS. 1998;95(7):3597–602.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Emery JG, McDonnell P, Burke MB, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998;273(23):14363–7.CrossRefPubMedGoogle Scholar
  3. 3.
    Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–19.CrossRefPubMedGoogle Scholar
  4. 4.
    Reid P, Holen I. Pathophysiological roles of osteoprotegerin (OPG). Eur J Cell Biol. 2009;88(1):1–17.CrossRefPubMedGoogle Scholar
  5. 5.
    Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62(6):1619–23.PubMedGoogle Scholar
  6. 6.
    Neville-Webbe HL, Cross NA, Eaton CL, et al. Osteoprotegerin (OPG) produced by bone marrow stromal cells protects breast cancer cells from TRAIL-induced apoptosis. Breast Cancer Res Treat. 2004;86(3):269–79.CrossRefPubMedGoogle Scholar
  7. 7.
    Shipman CM, Croucher PI. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 2003;63(5):912–6.PubMedGoogle Scholar
  8. 8.
    Holen I, Cross SS, Neville-Webbe HL, et al. Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo–a role in tumour cell survival? Breast Cancer Res Treat. 2005;92(3):207–15.CrossRefPubMedGoogle Scholar
  9. 9.
    Cross SS, Yang Z, Brown NJ, et al. Osteoprotegerin (OPG)–a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int J Cancer. 2006;118(8):1901–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Benslimane-Ahmim Z, Heymann D, Dizier B, et al. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. J Thromb Haemost. 2011;9(4):834–43.CrossRefPubMedGoogle Scholar
  11. 11.
    Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immun. 1995;3(6):673–82.CrossRefGoogle Scholar
  12. 12.
    Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996;271(22):12687–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Schramek D, Leibbrandt A, Sigl V, et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature. 2010;468(7320):98–102.CrossRefPubMedCentralPubMedGoogle Scholar
  14. 14.
    Gonzalez-Suarez E, Jacob AP, Jones J, et al. RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature. 2010;468(7320):103–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470(7335):548–53.CrossRefPubMedCentralPubMedGoogle Scholar
  16. 16.
    Vik A, Mathiesen EB, Brox J, et al. Serum osteoprotegerin is a predictor for incident cardiovascular disease and mortality in a general population: the Tromso Study. J Thromb Haemost. 2011;9(4):638–44.CrossRefPubMedGoogle Scholar
  17. 17.
    Vik A, Mathiesen EB, Johnsen SH, et al. Serum osteoprotegerin, sRANKL and carotid plaque formation and growth in a general population—the Tromso study. J Thromb Haemost. 2010;8(5):898–905.PubMedGoogle Scholar
  18. 18.
    Larsen IK, Småstuen M, Johannesen TB, et al. Data quality at the cancer registry of Norway: an overview of comparability, completeness, validity and timeliness. Eur J Cancer. 2009;45(7):1218–31.CrossRefPubMedGoogle Scholar
  19. 19.
    Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109(18):2175–80.CrossRefPubMedGoogle Scholar
  20. 20.
    Kiechl S, Willeit J, Schett G, et al. Denosumab, Osteoporosis, and prevention of fractures. N Engl J Med. 2009;361(22):2188–91.CrossRefPubMedGoogle Scholar
  21. 21.
    Ito R, Nakayama H, Yoshida K, et al. Expression of osteoprotegerin correlates with aggressiveness and poor prognosis of gastric carcinoma. Virchows Arch. 2003;443(2):146–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Pettersen I, Bakkelund W, Smedsrød B, Sveinbjørnsson B. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 2005;25(6B):3809–16.PubMedGoogle Scholar
  23. 23.
    De Toni EN, Thieme SE, Herbst A, et al. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin Cancer Res. 2008;14(15):4713–8.CrossRefPubMedGoogle Scholar
  24. 24.
    Lipton A, Ali SM, Leitzel K, et al. Serum osteoprotegerin levels in healthy controls and cancer patients. Clin Cancer Res. 2002;8(7):2306–10.PubMedGoogle Scholar
  25. 25.
    Tsukamoto S, Ishikawa T, Iida S, et al. Clinical significance of osteoprotegerin expression in human colorectal cancer. Clin Cancer Res. 2011;17(8):2444–50.CrossRefPubMedGoogle Scholar
  26. 26.
    Canon J, Bryant R, Roudier M, Branstetter DG, Dougall WC. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model. Breast Cancer Res Treat. 2012;135(3):771–80.CrossRefPubMedGoogle Scholar
  27. 27.
    Santini D, Schiavon G, Vincenzi B, et al. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients. PLoS ONE. 2011;6(4):e19234.CrossRefPubMedCentralPubMedGoogle Scholar
  28. 28.
    Kamiya N, Suzuki H, Endo T, et al. Significance of serum osteoprotegerin and receptor activator of nuclear factor κB ligand in Japanese prostate cancer patients with bone metastasis. Int J Clin Oncol. 2011;16(4):366–72.CrossRefGoogle Scholar
  29. 29.
    Peng X, Guo W, Ren T, et al. Differential expression of the RANKL/RANK/OPG system is associated with bone metastasis in human non-small cell lung cancer. PLoS ONE. 2013;8(3):e58361.CrossRefPubMedCentralPubMedGoogle Scholar
  30. 30.
    Van Geelen CM, de Vries EG, de Jong S. Lessons from TRAIL-resistance mechanisms in colorectal cancer cells: paving the road to patient-tailored therapy. Drug Resist Updates. 2004;7(6):345–58.CrossRefGoogle Scholar
  31. 31.
    Ryser MD, Qu Y, Komarova SV. Osteoprotegerin in bone metastases: mathematical solution to the puzzle. PLoS Comput Biol. 2012;8(10):e1002703.CrossRefPubMedCentralPubMedGoogle Scholar
  32. 32.
    Vik A, Brodin E, Sveinbjornsson B, Hansen JB. Heparin induces mobilization of osteoprotegerin into the circulation. Thromb Haemost. 2007;98(1):148–54.PubMedGoogle Scholar
  33. 33.
    Kiechl S, Schett G, Schwaiger J, et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation. 2007;116(4):385–91.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  • Anders Vik
    • 1
    • 2
  • Ellen E. Brodin
    • 1
    • 2
  • Ellisiv B. Mathiesen
    • 3
    • 4
  • Jan Brox
    • 1
    • 5
  • Lone Jørgensen
    • 6
    • 7
  • Inger Njølstad
    • 8
  • Sigrid K. Brækkan
    • 1
    • 2
  • John-Bjarne Hansen
    • 1
    • 2
  1. 1.Hematological Research Group (HERG), Department of Clinical MedicineUniversity of TromsøTromsøNorway
  2. 2.Division of Internal MedicineUniversity Hospital of North NorwayTromsøNorway
  3. 3.Brain and Circulation Research Group, Department of Clinical MedicineUniversity of TromsøTromsøNorway
  4. 4.Department of Neurology and Clinical NeurophysiologyUniversity Hospital of North NorwayTromsøNorway
  5. 5.Division of Laboraory MedicineUniversity Hospital of North NorwayTromsøNorway
  6. 6.Department of Health and Care SciencesUniversity of TromsøTromsøNorway
  7. 7.Department of Clinical Therapeutic ServicesUniversity Hospital of North NorwayTromsøNorway
  8. 8.Department of Community MedicineUniversity of TromsøTromsøNorway

Personalised recommendations